KRYS
Price
$138.88
Change
-$3.70 (-2.60%)
Updated
Jun 27 closing price
Capitalization
4.01B
43 days until earnings call
XERS
Price
$4.70
Change
-$0.04 (-0.84%)
Updated
Jun 27 closing price
Capitalization
752.73M
39 days until earnings call
Interact to see
Advertisement

KRYS vs XERS

Header iconKRYS vs XERS Comparison
Open Charts KRYS vs XERSBanner chart's image
Krystal Biotech
Price$138.88
Change-$3.70 (-2.60%)
Volume$418.51K
Capitalization4.01B
Xeris Biopharma Holdings
Price$4.70
Change-$0.04 (-0.84%)
Volume$4.69M
Capitalization752.73M
KRYS vs XERS Comparison Chart in %
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. XERS commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Buy and XERS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (KRYS: $138.88 vs. XERS: $4.70)
Brand notoriety: KRYS and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 112% vs. XERS: 215%
Market capitalization -- KRYS: $4.01B vs. XERS: $752.73M
KRYS [@Biotechnology] is valued at $4.01B. XERS’s [@Biotechnology] market capitalization is $752.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than XERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 4 TA indicator(s) are bullish while XERS’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 4 bullish, 5 bearish.
  • XERS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, XERS is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а +4.85% price change this week, while XERS (@Biotechnology) price change was +4.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

XERS is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.01B) has a higher market cap than XERS($753M). XERS YTD gains are higher at: 38.643 vs. KRYS (-11.349). KRYS has higher annual earnings (EBITDA): 140M vs. XERS (-4.34M). KRYS has more cash in the bank: 617M vs. XERS (58.4M). KRYS has less debt than XERS: KRYS (9.66M) vs XERS (269M). KRYS has higher revenues than XERS: KRYS (333M) vs XERS (223M).
KRYSXERSKRYS / XERS
Capitalization4.01B753M533%
EBITDA140M-4.34M-3,227%
Gain YTD-11.34938.643-29%
P/E Ratio33.30N/A-
Revenue333M223M149%
Total Cash617M58.4M1,057%
Total Debt9.66M269M4%
FUNDAMENTALS RATINGS
KRYS vs XERS: Fundamental Ratings
KRYS
XERS
OUTLOOK RATING
1..100
228
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
41100
SMR RATING
1..100
57100
PRICE GROWTH RATING
1..100
6142
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (71) in the Pharmaceuticals Major industry is in the same range as XERS (91). This means that KRYS’s stock grew similarly to XERS’s over the last 12 months.

KRYS's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for XERS (100). This means that KRYS’s stock grew somewhat faster than XERS’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for XERS (100). This means that KRYS’s stock grew somewhat faster than XERS’s over the last 12 months.

XERS's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as KRYS (61). This means that XERS’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as XERS (100). This means that KRYS’s stock grew similarly to XERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSXERS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 12 days ago
76%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRGCX42.290.22
+0.52%
MFS Core Equity C
CVQZX8.890.03
+0.34%
Columbia Disciplined Value Inst
RPEAX40.280.06
+0.15%
Davis Opportunity A
TSMUX15.15N/A
N/A
Nuveen Quant Small/Mid Cap Eq W
WGGSX13.56N/A
N/A
Wasatch Global Select Institutional

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-2.60%
XNCR - KRYS
54%
Loosely correlated
-3.10%
CRNX - KRYS
54%
Loosely correlated
-0.10%
IDYA - KRYS
54%
Loosely correlated
-4.13%
ACLX - KRYS
54%
Loosely correlated
+0.90%
CGON - KRYS
54%
Loosely correlated
-0.46%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-0.84%
TRDA - XERS
51%
Loosely correlated
-1.57%
YMAB - XERS
45%
Loosely correlated
-2.08%
XNCR - XERS
45%
Loosely correlated
-3.10%
CGON - XERS
44%
Loosely correlated
-0.46%
KRYS - XERS
43%
Loosely correlated
-2.60%
More